Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
49
INSM Quote, Financials, Valuation and Earnings
Last price:
$177.95
Seasonality move
:
4.92%
Day range:
$175.00 - $178.10
52-week range:
$60.40 - $212.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
75.50x
P/B ratio:
40.02x
Volume:
747.3K
Avg. volume:
3.7M
1-year change:
151.55%
Market cap:
$37.8B
Revenue:
$363.7M
EPS (TTM):
-$6.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.28% | -4.28% | $182.07 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
|
UTHR
United Therapeutics Corp.
|
$812.9M | $7.31 | 11.02% | 17.13% | $518.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$177.42 | $214.78 | $37.8B | -- | $0.00 | 0% | 75.50x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.69 | $491.92 | $52.9B | 1,666.07x | $0.00 | 0% | 16.44x |
|
BIIB
Biogen, Inc.
|
$176.33 | $182.07 | $25.9B | 16.08x | $0.00 | 0% | 2.67x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
|
UTHR
United Therapeutics Corp.
|
$514.64 | $518.25 | $22.2B | 19.50x | $0.00 | 0% | 7.93x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
UTHR
United Therapeutics Corp.
|
-- | 1.213 | -- | 5.61x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
Insmed, Inc. vs. Competitors
-
Which has Higher Returns INSM or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 20.1%. Insmed, Inc.'s return on equity of -193.23% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About INSM or ALNY?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 21.15%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.77%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is INSM or ALNY More Risky?
Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock INSM or ALNY?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or ALNY?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Insmed, Inc.'s net income of -$370M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,666.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 75.50x versus 16.44x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.75.50x -- $142.3M -$370M ALNYAlnylam Pharmaceuticals, Inc.16.44x 1,666.07x $1.2B $251.1M
-
Which has Higher Returns INSM or BIIB?
Biogen, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 19%. Insmed, Inc.'s return on equity of -193.23% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About INSM or BIIB?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 21.15%. On the other hand Biogen, Inc. has an analysts' consensus of $182.07 which suggests that it could grow by 2.47%. Given that Insmed, Inc. has higher upside potential than Biogen, Inc., analysts believe Insmed, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 BIIBBiogen, Inc.14 18 1 -
Is INSM or BIIB More Risky?
Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock INSM or BIIB?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or BIIB?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Insmed, Inc.'s net income of -$370M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 75.50x versus 2.67x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.75.50x -- $142.3M -$370M BIIBBiogen, Inc.2.67x 16.08x $2.5B $466.5M
-
Which has Higher Returns INSM or CRMD?
CorMedix, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 49.9%. Insmed, Inc.'s return on equity of -193.23% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About INSM or CRMD?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 21.15%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Insmed, Inc., analysts believe CorMedix, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 CRMDCorMedix, Inc.4 0 0 -
Is INSM or CRMD More Risky?
Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock INSM or CRMD?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or CRMD?
Insmed, Inc. quarterly revenues are $142.3M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Insmed, Inc.'s net income of -$370M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 75.50x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.75.50x -- $142.3M -$370M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns INSM or PFE?
Pfizer Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 21.32%. Insmed, Inc.'s return on equity of -193.23% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About INSM or PFE?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 21.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Insmed, Inc. has higher upside potential than Pfizer Inc., analysts believe Insmed, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 PFEPfizer Inc.7 15 1 -
Is INSM or PFE More Risky?
Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock INSM or PFE?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Insmed, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or PFE?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Insmed, Inc.'s net income of -$370M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 75.50x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.75.50x -- $142.3M -$370M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
-
Which has Higher Returns INSM or UTHR?
United Therapeutics Corp. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 42.36%. Insmed, Inc.'s return on equity of -193.23% beat United Therapeutics Corp.'s return on equity of 19.2%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B -
What do Analysts Say About INSM or UTHR?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 21.15%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 0.7%. Given that Insmed, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Insmed, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 UTHRUnited Therapeutics Corp.8 5 0 -
Is INSM or UTHR More Risky?
Insmed, Inc. has a beta of 1.015, which suggesting that the stock is 1.49% more volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.
-
Which is a Better Dividend Stock INSM or UTHR?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or UTHR?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Insmed, Inc.'s net income of -$370M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while United Therapeutics Corp.'s PE ratio is 19.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 75.50x versus 7.93x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.75.50x -- $142.3M -$370M UTHRUnited Therapeutics Corp.7.93x 19.50x $799.5M $338.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
